扩展8p23.1缺失综合征表型:八例新发病例与22q11.2微缺失临床谱相似
该研究纳入118例先天性心脏病婴儿,旨在早期分子诊断22q11.2缺失综合征,其中8例经MLPA和微阵列检测发现8p23.1缺失,临床特征与22q11.2微缺失谱重叠。细胞基因组筛查可有效鉴别诊断并排除其他综合征,强调早期诊断和临床随访对微缺失综合征的重要性。
要点
- 8p23.1缺失综合征临床表现与22q11.2微缺失谱重叠,诊断具有挑战性。
- 在118例先天性心脏病婴儿中,MLPA和微阵列检测发现8例8p23.1缺失。
- 细胞基因组筛查有助于精确诊断和鉴别其他共存综合征。
核心结论
- 细胞基因组筛查能有效建立鉴别诊断并排除其他共存综合征。
- 8p23.1缺失综合征临床图像具有挑战性,但细胞基因组工具可提供精确诊断并帮助阐明基因型-表型复杂性。
- 早期诊断和临床随访对微缺失综合征至关重要。
研究设计与样本
- 本研究为先前研究的一部分,该先前研究旨在对118例先天性心脏病婴儿进行22q11.2缺失综合征的早期分子诊断。
- 采用MLPA检测(SALSA MLPA探针试剂盒P064-B2、P036-E1、P070-B2、P356-A1和P250-B1)进行比较基因组筛查以确认临床诊断。
- 随后使用Infinium CytoSNP-850K BeadChip进行基因组微阵列以确认缺失、确定断点并搜索基因组拷贝数变异。
主要发现
- 使用3种不同MLPA试剂盒在5例患者中检测到8p23.1典型缺失,涉及PPP1R3B、MSRA和GATA4基因。
- 对5例患者及另外3例临床怀疑22q11缺失的患者(共8例)进行微阵列分析,精确界定了断点并排除了其他基因组异常。
临床怎么用
- 对先天性心脏病婴儿,尤其是临床怀疑22q11.2缺失者,应考虑细胞基因组筛查以鉴别8p23.1缺失综合征。
- 早期分子诊断有助于精确诊断、排除其他综合征并指导临床随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the effectiveness of early molecular diagnosis in the clinical management of rare diseases, presenting 8 patients with 8p23.1DS who have clinical features that overlap the phenotypic spectrum of 22q11.2DS. STUDY DESIGN: This report is part of a previous study that aims to provide a precocious molecular diagnosis of the 22q11.2 deletion syndrome in 118 infants with congenital heart disease. To confirm the clinical diagnosis, patients underwent comparative genomic screening by the multiplex ligation-dependent probe amplification (MLPA) assay with the SALSA MLPA probemix kits P064-B2, P036-E1, P070-B2, P356-A1, and P250- B1. Subsequently, the patients performed the genomic microarray using the Infinium CytoSNP-850K BeadChip to confirm the deletion, determine the breakpoints of the deletion, and search for genomic copy number variations. RESULTS: MLPA performed with 3 different kits revealed the 8p23.1 typical deletion involving the PPP1R3B, MSRA, and GATA4 genes in the 5 patients. The array analysis was performed on these 5 patients and 3 other patients (8 patients) who also had clinical suspicion of 22q11 deletion (8 patients) allowed a precise definition of the breakpoints and excluded other genomic abnormalities. CONCLUSIONS: Cytogenomic screening was efficient in establishing a differential diagnosis and ruling out the presence of other concomitant syndromes. The clinical picture of the 8p23.1 deletion syndrome is challenging; however, cytogenomic tools can provide an exact diagnosis and help to clarify the genotype-phenotype complexity of these patients. Our reports underline the importance of early diagnosis and clinical follow-up of microdeletion syndromes.
引用
- Montenegro MM, Camilotti D, Quaio CRDC, et al. Expanding the Phenotype of 8p23.1 Deletion Syndrome: Eight New Cases Resembling the Clinical Spectrum of 22q11.2 Microdeletion. J Pediatr. 2022. PMID: 36067875. doi:10.1016/j.jpeds.2022.08.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。